22h
Crispr And Intellia: Advancing In Vivo Gene Editing As 2025 Results Strengthen Investment Outlook
Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...
The Procter & Gamble Company ( NYSE: PG) Q1 2026 Earnings Call October 24, 2025 8:30 AM EDT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback